Clinical resistance to imatinib (IM) in chronic myeloid leukemia (CML) carries adverse consequences. We investigated 22 CML patients who developed IM-resistance for BCR-ABL kinase domain (KD) mutations. The median follow-up for this study was 101.9 months (range: 22.2 to 176.5 months) and the estimated mean overall survival was 150.87 months (95% CI: 130.0 to 171.0). Five out of 22 patients tested positive for BCR-ABL KD mutations: 2 had T315I, 2 had E255K and 1 had V289F mutations. Of the remaining 17 patients who did not harbor BCR-ABL KD mutations, 11 patients received nilotinib while the rest continued on IM. All 17 achieved haematological remission but only 5 patients achieved complete cytogenetic remission, 4 of whom did so after switching to nilotinib. Our study shows that most of our IM-resistant patients do not test positive for BCR-ABL KD mutations by available testing methods and the role of second generation tyrosine kinase inhibitors remains undetermined. A critical analysis of the BCR-ABL KD mutations and the underlying mechanisms/ pathways of BCR-ABL independent IM-resistance along with potential treatments in the horizon will be discussed.

1. Baccarani, M., Deininger, M. W., Rosti, G., et al. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122, 872–884.
2. Bhamidipati, P. K., Kantarjian, H., Cortes, J., Cornelison, A. M., & Jabbour, E. (2013). Management of imatinib-resistant patients with chronic myeloid leukemia. Therapeutic Advances in Hematology, 4, 103–117.
3. Bixby, D., & Talpaz, M. (2009). Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology: American Society of Hematology Education Program, 461–476.
4. Branford, S., Melo, J. V., & Hughes, T. P. (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter? Blood, 114, 5426–5435.
5. Burchert, A., Wang, Y., Cai, D., et al. (2005). Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia, 19, 1774–1782.
6. Chahardouli, B., Zaker, F., Mousavi, S. A., et al. (2013). Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance. Hematology, 18, 158–162.
7. Chai, S. K., Nichols, G. L., & Rothman, P. (1997). Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. Journal of Immunology, 159, 4720–4728.
8. Crossman, L. C., Druker, B. J., Deininger, M. W., Pirmohamed, M., Wang, L., & Clark, R. (2005). hOCT 1 and resistance to imatinib. Blood, 106, 1133–1134.
9. Di Stefano, C., Mirone, G., Perna, S., & Marfe, G. (2016). The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia. Oncology Reports, 35, 614–624.
10. Elias, M. H., Baba, A. A., Husin, A., et al. (2012). Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome-positive Malaysian chronic myeloid leukemia patients. Hematology Reports, 4, e23.
11. Fallah, P., Amirizadeh, N., Poopak, B., et al. (2015). Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase. International Journal of Laboratory Hematology, 37, 560–568.
12. Ferrao, P. T., Frost, M. J., Siah, S. P., & Ashman, L. K. (2003). Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood, 102, 4499–4503.
13. Flamant, S., Ritchie, W., Guilhot, J., et al. (2010). Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica, 95, 1325–1333.
14. Gorre, M. E., Mohammed, M., Ellwood, K., et al. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876–880.
15. Hochhaus, A., & La Rosée, P. (2004). Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia, 18, 1321–1331.
16. Hoover, R. R., Mahon, F. X., Melo, J. V., & Daley, G. Q. (2002). Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood, 100, 1068–1071.
17. Hughes, T., Deininger, M., Hochhaus, A., et al. (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108, 28–37.
18. Hughes, T., Saglio, G., Branford, S., et al. (2009). Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. Journal of Clinical Oncology, 27, 4204–4210.
19. Hughes, T. P., Kaeda, J., Branford, S., et al. (2003). Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. The New England Journal of Medicine, 349, 1423–1432.
20. Jabbour, E., Jones, D., Kantarjian, H., et al. (2009). Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood, 114, 2037–2043.
21. Khorashad, J. S., Anand, M., Marin, D., et al. (2006). The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia, 20, 658–663.
22. Lange, T., Ernst, T., Gruber, F. X., et al. (2013). The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica, 98, 714–717.
23. Martinelli, G., Soverini, S., Rosti, G., Cilloni, D., & Baccarani, M. (2005). New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica, 90, 534–541.
24. National Comprehensive Cancer Network. (2015). Chronic myelogenous leukemia. http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
25. O’Brien, S. G., Guilhot, F., Larson, R., et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The New England Journal of Medicine, 348, 994–1004.
26. Peng, X. X., Tiwari, A. K., Wu, H. C., & Chen, Z. S. (2012). Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chinese Journal of Cancer, 31, 110–118.
27. Picard, S., Titier, K., Etienne, G., et al. (2007). Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 109, 3496–3499.
28. Puil, L., Liu, J., Gish, G., et al. (1994). Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. The EMBO Journal, 13, 764–773.
29. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science, 289, 1938–1942.
30. Sekulić, A., Hudson, C., Homme, J., et al. (2000). A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Research, 60, 3504–3513.
31. Sherbenou, D. W., Wong, M. J., Humayun, A., et al. (2007). Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia, 21, 489–493.
32. Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., et al. (1995). Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood, 86, 726–736.
33. Soverini, S., Colarossi, S., Gnani, A., et al. (2006). Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clinical Cancer Research, 12, 7374–7379.
34. Soverini, S., Hochhaus, A., Nicolini, F. E., et al. (2011). BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 118, 1208–1215.
35. Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004). Active transport of imatinib into and out of cells: Implications for drug resistance. Blood, 104, 3739–3745.
36. Valent, P. (2007). Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. Biologics, 1, 433–448.